Latest Conference Articles

October 25th 2018, 5:21am

ESMO Congress

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, chair, Head and Neck Surgery director, Institute of Head and Neck Studies and Education at the School of Cancer Studies, University of Birmingham, discusses the new staging system for patients with HPV-positive head and neck cancer.

October 23rd 2018, 8:59pm

ESMO Congress: Lung Cancer

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the primary efficacy results from the B-F1RST trial in non–small cell lung cancer (NSCLC).

October 23rd 2018, 8:57pm

ESMO Congress: Breast Cancer

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses findings from the IMpassion130 trial in triple-negative breast cancer (TNBC).

October 23rd 2018, 7:58pm

State of the Science Summit on Hematologic Malignancies

Geoffrey Uy, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine, Siteman Cancer Center, discusses therapy selection in acute myeloid leukemia (AML).

October 23rd 2018, 1:34am

State of the Science Summit on GI Malignancies

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses second- and third-line therapies in gastric cancer.

October 23rd 2018, 1:29am

ESMO Congress: Lung Cancer

Asian patients with untreated ALK-positive advanced NSCLC lived significantly longer without disease progression if they received the next-generation tyrosine kinase inhibitor alectinib instead of crizotinib as initial therapy.

October 23rd 2018, 12:18am

ESMO Congress: GI Cancers

First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.

October 22nd 2018, 11:24pm

ESMO Congress: Lung Cancer

The first-line triplet of atezolizumab, carboplatin, and nab-paclitaxel was associated with a statistically significant improvement in both progression-free and overall survival compared with chemotherapy alone in patients with stage IV nonsquamous NSCLC, according to results from the phase III IMpower130 trial.

October 22nd 2018, 10:53pm

ESMO Congress: Head and Neck Cancer

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses findings from the KEYNOTE-048 in head and neck squamous cell carcinoma (HNSCC).

October 22nd 2018, 10:52pm

ESMO Congress: GU Cancers

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in newly diagnosed prostate cancer.

October 22nd 2018, 9:28pm

ESMO Congress: Head and Neck Cancer

Cisplatin plus radiotherapy results in better overall survival and the same rate of all-grade toxicity compared with cetuximab plus radiotherapy in patients with HPV-positive oropharyngeal cancer.

October 22nd 2018, 8:58pm

ESMO Congress

Long-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treated with adjuvant dabrafenib plus trametinib.

October 22nd 2018, 8:11pm

ESMO Congress: GI Cancers

Trifluridine/tipiracil reduces the risk of death by about one-third compared with placebo in patients with heavily pretreated gastric or gastroesophageal junction cancer.

October 22nd 2018, 7:58pm

ESMO Congress: Head and Neck Cancer

Frontline pembrolizumab monotherapy showed an improvement in overall survival and duration of response versus standard therapy in patients with PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma; however, there was not a similar improvement in progression-free survival or overall response rate with the PD-1 inhibitor.

October 22nd 2018, 5:33pm

ESMO Congress: GI Cancers

The combination of the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab showed promising and durable antitumor activity in a phase Ib study of patients with advanced hepatocellular carcinoma.

October 22nd 2018, 5:08pm

ESMO Congress: GU Cancers

Preliminary data from the ongoing phase II TRITON2 trial demonstrated a 44% confirmed objective response rate by investigator assessment among evaluable men with BRCA1/2-mutated metastatic castration-resistant prostate cancer who were treated with the PARP inhibitor rucaparib.

October 22nd 2018, 2:56am

ESMO Congress: GU Cancers

Extended follow-up data from the CheckMate-032 study shows a trend toward higher overall response and longer progression-free survival with the regimen of nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg in patients with platinum-pretreated metastatic urothelial carcinoma.

October 22nd 2018, 1:44am

ESMO Congress: Lung Cancer

More than half of patients with advanced solid tumors associated with NTRK gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.

October 22nd 2018, 1:14am

ESMO Congress: Gynecologic Cancers

The PARP inhibitor olaparib significantly improved progression-free survival as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.

October 21st 2018, 11:01pm

ESMO Congress

Patients with advanced cancers associated with NTRK gene fusions had an 80% objective response rate with the TRK inhibitor larotrectinib, pooled results from three small trials showed.